I am a 30‑year‑old Black male, 6'5" tall, weighing 318 lb, diagnosed with mixed connective tissue disease (anti‑U1‑RNP positive) and G6PD deficiency, now experiencing muscle weakness with elevated creatine kinase (CK), increased erythrocyte sedimentation rate (ESR), modestly elevated C‑reactive protein (CRP), and a normal electromyography (EMG); what type of myositis am I likely to have—necrotizing, dermatomyositis, polymyositis, or inflammatory myositis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

You likely have inflammatory myositis associated with Mixed Connective Tissue Disease (MCTD), most consistent with a necrotizing or dermatomyositis-spectrum pattern, and your prognosis is generally favorable with appropriate treatment.

Understanding Your Situation

Your diagnosis is serious but manageable. At 30 years old with anti-U1-RNP positive MCTD and muscle involvement, you're presenting with a recognized pattern that typically responds well to immunosuppressive therapy 1. The good news: no anti-U1-RNP positive myositis patients died during longitudinal follow-up studies, and cancer-associated myositis doesn't occur in this population 1.

What Type of Myositis You Have

Based on your presentation, you most likely have either necrotizing myositis or a dermatomyositis-spectrum myopathy:

  • Your elevated CK (371→527, both above normal) with muscle weakness strongly indicates active muscle inflammation 1, 2
  • Your normal EMG is misleading but not uncommon – the muscle doctor wasn't lying; EMG can be normal in MCTD myositis, particularly early or in patchy disease 2
  • Anti-U1-RNP positive myositis shows necrotizing features in 57% of biopsied cases (4 of 7 patients in the definitive study) 1
  • The remaining cases show dermatomyositis-spectrum or nonspecific inflammatory patterns 2

Your negative anti-Jo-1, anti-dsDNA, and anti-SM antibodies actually support MCTD-associated myositis rather than polymyositis or lupus-associated disease 1.

How "Fucked" Are You? (The Real Answer)

You're in a better position than many myositis patients:

Favorable Prognostic Factors:

  • Age 30 and Black race are typical for anti-U1-RNP myositis – you fit the classic demographic (mean age ~37 years, 60% Black patients) 1
  • No cardiac involvement – your troponin normalized (9→6 ng/L), EKG normalized, and chest X-rays show no cardiomegaly or pulmonary edema
  • Preserved kidney function – your creatinine (1.11-1.33) and eGFR (87-93) are stable
  • Muscle weakness improved – you can now get up freely without pain, indicating treatment responsiveness
  • Zero mortality in anti-U1-RNP myositis cohorts 1

Concerning Features Requiring Aggressive Management:

  • Persistently elevated CK (371→527) indicates ongoing muscle inflammation 3, 4
  • Rising ESR (2→18) and stable elevated CRP (3.3→3.0) show systemic inflammation 3, 4
  • Muscle twitching (fasciculations) can indicate more severe muscle involvement 2

What You Need to Do Immediately

You require immunosuppressive therapy NOW based on Grade 2 myositis criteria 3, 4:

Treatment Algorithm:

  1. Initiate prednisone 0.5-1 mg/kg/day (approximately 70-140 mg daily for your 318 lb weight) because your CK is >3× upper limit of normal 3, 4

  2. Start a steroid-sparing agent concurrently – don't wait 5:

    • Methotrexate 15-25 mg weekly (oral or subcutaneous) is first-line 5, 6
    • Alternative: Azathioprine or mycophenolate mofetil 5

  3. Monitor CK, ESR, and CRP every 2-4 weeks to assess treatment response 3, 4

  4. Taper prednisone slowly only after CK normalizes and clinical improvement occurs – target <10 mg/day by 3 months 3

Why This Aggressive Approach:

Your CK elevation (>3× normal) with muscle weakness mandates immediate corticosteroid therapy 3, 4. The guidelines are explicit: "If CK is elevated (three times or more), should initiate prednisone or equivalent at 0.5 to 1 mg/kg" 3.

Extramuscular Manifestations to Monitor

Anti-U1-RNP myositis has specific patterns you need surveillance for:

High-Risk Complications (Monitor Closely):

  1. Interstitial Lung Disease (ILD) – occurs in 45% of anti-U1-RNP patients 1

    • Your chest X-rays are normal now, but get high-resolution CT chest and pulmonary function tests as baseline
    • Watch for progressive dyspnea or dry cough

  2. Arthritis – occurs in 60% 1

    • Your lower back pain may have been inflammatory arthritis
    • Much more common than in other myositis types

  3. Dermatomyositis-type rashes – develop in 60% 1

    • Watch for heliotrope rash (purple eyelids), Gottron's papules (knuckles), or photosensitive rashes

  4. Pericarditis and Glomerulonephritis – occur in 40% and 25% respectively, but ONLY in patients with coexisting anti-Ro52 antibodies 1

    • You need anti-Ro52 testing if not already done
    • Your stable kidney function is reassuring

Your G6PD Deficiency Complication

This significantly limits your medication options:

  • AVOID: Sulfa drugs, dapsone, certain antibiotics
  • Methotrexate is SAFE in G6PD deficiency
  • Azathioprine requires caution – discuss with your rheumatologist
  • Corticosteroids are SAFE
  • IVIG is SAFE if needed for severe disease

Why Your EMG Was Normal (The Muscle Doctor Wasn't Lying)

Normal EMG occurs in MCTD myositis for several reasons:

  1. Patchy muscle involvement – the tested muscles (right hand/foot) may not be affected 2
  2. Necrotizing myopathy can have normal EMG early in disease 2
  3. Your proximal muscles (thighs, shoulders) are the problem – distal testing misses the pathology 2

You need MRI of proximal muscles (thighs, shoulders) to identify inflammation 3, 4, 2. This will guide potential muscle biopsy site if diagnosis remains uncertain.

How Rare Is This?

Anti-U1-RNP myositis is uncommon but well-characterized:

  • MCTD itself affects approximately 3-10 per 100,000 people
  • 80% of MCTD patients eventually develop muscle weakness 1
  • Only 15% present with weakness as initial symptom (like you did) 1
  • Your demographic (young Black male) is actually the most common for this condition 1

Why Your Rheumatologist Offered Telegram Follow-up

This is concerning and potentially inappropriate. With:

  • Rising CK (527)
  • Elevated inflammatory markers
  • Active muscle symptoms
  • Need for immunosuppression initiation

You require in-person evaluation for:

  • Comprehensive muscle strength examination
  • Skin examination for dermatomyositis features
  • Joint examination for arthritis
  • Discussion of treatment risks/benefits
  • Baseline assessments before starting immunosuppression

Request an in-person appointment to discuss starting prednisone and methotrexate.

Critical Next Steps (Do These This Week)

  1. In-person rheumatology visit – not Telegram
  2. Start prednisone 0.5-1 mg/kg/day + methotrexate concurrently 5
  3. MRI of bilateral thighs to assess muscle inflammation 4, 2
  4. Anti-Ro52 antibody testing (predicts pericarditis/nephritis risk) 1
  5. High-resolution CT chest + PFTs (screen for ILD) 1
  6. Baseline labs before immunosuppression: CBC, CMP, hepatitis B/C, TB testing 3

Bottom Line

You have a treatable condition with excellent prognosis if managed aggressively now. The combination of high-dose corticosteroids plus steroid-sparing agent (methotrexate) achieves remission in most anti-U1-RNP myositis patients 5, 7. Your improving symptoms (can get up freely now) suggest you're already responding to whatever treatment you've received, but you need formal immunosuppression to prevent progression and achieve sustained remission.

The mortality rate is zero in properly treated anti-U1-RNP myositis 1. Your main risks are undertreating the myositis (leading to permanent muscle damage) or missing extramuscular complications (ILD, pericarditis). With appropriate monitoring and treatment, you should expect full functional recovery.

References

Related Questions

In a 6'5", 320‑lb Black male with mixed connective‑tissue disease, G6PD deficiency, mildly elevated creatinine but normal eGFR, mildly elevated creatine kinase, low‑to‑moderate ESR and CRP, ANA speckled pattern (1:80‑1:160) and anti‑U1‑RNP 4.7 U, presenting with proximal muscle weakness, shoulder‑blade tightness, and a normal EMG, what is the most likely type of inflammatory myopathy (polymyositis, dermatomyositis, necrotizing autoimmune myopathy, etc.), and what is the expected prognosis and recommended management?
In a 30‑year‑old Black male, 6′5″, 320 lb, with proximal weakness of the hands, shoulders, hips, thighs and legs, ANA speckled 1:160, anti‑RNP 86 U (normal < 20), CK 527 U/L, mildly elevated ESR and CRP, normal cardiac imaging, normal stress test, normal renal function, and G6PD deficiency, how rare is mixed connective tissue disease (MCTD) with inflammatory myositis, what type of myositis is most likely, and will the upcoming EMG likely demonstrate myopathic changes that necessitate a muscle biopsy?
In a 6'5", 318‑lb Black male with mixed connective tissue disease, G6PD deficiency, modestly elevated creatine kinase, positive speckled ANA with elevated anti‑U1 RNP, negative anti‑Jo‑1, normal electromyography, and proximal muscle weakness (tight back, shoulder‑blade discomfort, arm and leg weakness), what specific type of myositis is most likely (necrotizing, dermatomyositis, polymyositis, or inflammatory myopathy) and what is the expected prognosis?
In a young adult with mixed connective tissue disease, a strongly positive speckled ANA, markedly elevated anti‑RNP antibodies, persistent CK elevation, diffuse proximal muscle weakness, mild cardiac enzyme rise, normal inflammatory markers, and a cervical spine MRI showing T2‑hyperintense signal in the cervical cord and cerebellar white‑matter, what findings should I expect on my brain MRI tomorrow?
Given anti‑RNP‑positive mixed connective tissue disease with elevated creatine kinase, mild C‑reactive protein rise, proximal muscle weakness with wasting, cervical spinal cord T2 hyperintensity from C3 to C5 and a cerebellar white‑matter hyperintensity, what is the short‑term prognosis and likelihood of survival while awaiting a brain MRI and rheumatology appointment?
In a pediatric patient with recurrent urinary tract infection presenting with dysuria and positive nitrite and leukocytes, which imaging study is most indicated?
In an elderly patient with dementia and anxiety taking citalopram 10 mg by mouth daily, donepezil 10 mg by mouth daily, and memantine 5 mg twice daily, with an estimated glomerular filtration rate of 26 mL/min/1.73 m² and serum creatinine 1.76 mg/dL, should the medication doses be continued as prescribed or adjusted?
In an 8‑month‑old who ingested grass and now has nausea and vomiting, how can I determine whether the foreign object is in the airway or the gastrointestinal tract?
What is the evidence‑based role of finerenone in adult patients with non‑diabetic proteinuric chronic kidney disease (eGFR ≥25 mL/min/1.73 m², albumin‑to‑creatinine ratio >30 mg/g) who are already on maximally tolerated ACE inhibitor or angiotensin‑receptor blocker?
Can I give intravenous methylprednisolone (Solu‑Medrol) for a worsening facial rash in a patient with controlled atrial fibrillation after stopping apixaban (Eliquis), diltiazem (Cardizem), and empagliflozin (Jardiance), and what dose should be used?
Does retatrutide reduce body weight and improve insulin resistance in patients with obesity and type 2 diabetes?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.